SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient With Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes

Internal Medicine - Japan
doi 10.2169/internalmedicine.4323-19
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Japanese Society of Internal Medicine

Related search

Combining SGLT2 Inhibitor and GLP-1 Agonist: Exaggerated Weight Loss in a Morbidly Obese Patient With Type 2 Diabetes

British Journal of Diabetes
2016English

SGLT2 Inhibitors or GLP-1 Receptor Agonists as Second-Line Therapy in Type 2 Diabetes: Patient Selection and Perspectives

Vascular Health and Risk Management
2016English

Qtern: DPP-4 and SGLT2 Inhibitor Combination for Type 2 Diabetes

Prescriber
Pharmacology
2017English

Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

DPP-4/SGLT2 Inhibitor Combined Therapy for Type 2 Diabetes

Prescriber
Pharmacology
2017English

Patient Preferences for Frequency of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Injections in the Treatment of Type 2 Diabetes

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Effective SGLT2 Inhibitor for Patient With Type 2 Diabetes Mellitus (T2DM) and Depression

2020English

Dulaglutide: Third Once-Weekly GLP-1 Agonist for Type 2 Diabetes

Pharmacy Today
2014English

Ertugliflozin: A New SGLT2 Inhibitor for Type 2 Diabetes

Prescriber
Pharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy